KRON Insider Trading Activity and SEC Form 4 Filings
KRON insider trading summary
No open-market insider purchases or sales of Kronos Bio, Inc. (KRON) have been reported on SEC Form 4 in the past 12 months.
Latest KRON insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 5, 2025 | Deborah Knobelman | President & Interim CEO | Sell | $22K (24,838 @ $0.87) |
| Jun 28, 2024 | Norbert W Bischofberger | President & CEO | Buy | $255K (204,670 @ $1.25) |
| Jun 27, 2024 | Norbert W Bischofberger | President & CEO | Buy | $479K (410,848 @ $1.17) |
| Jun 12, 2024 | Norbert W Bischofberger | President & CEO | Buy | $1.1M (881,913 @ $1.24) |
| Jun 11, 2024 | Norbert W Bischofberger | President & CEO | Buy | $815K (744,308 @ $1.09) |
| Jun 10, 2024 | Norbert W Bischofberger | President & CEO | Buy | $1.2M (1,378,901 @ $0.88) |
| Feb 21, 2024 | Charles Y Lin | Sr VP, Research & Development | Sell | $13K (12,036 @ $1.05) |
| Feb 21, 2024 | Elizabeth A Olek | Sr VP, Clinical Science | Sell | $8K (7,368 @ $1.05) |
| Feb 21, 2024 | Allison Frisbee | Sr VP, Corp Operations & Legal | Sell | $13K (12,105 @ $1.05) |
| Jan 4, 2024 | Jorge DiMartino | Chief Medical Officer & VP | Sell | $14K (12,009 @ $1.18) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.